StockWatch
·

HESTER BIOSCIENCES LTD.

BSE: 524669

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
84.60
+13.8%+28.1%
Expenditure
62.26
+14.1%+10.8%
Net Profit
16.66
+13.2%+131.1%
OPM %
32.94%
-0.57pp+14.54pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0027.4154.8282.23109.64Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Revenue Growth Masks a Profit Collapse That Management Won't Explain

biologicals pipeline · Africa expansion · profit collapse

Result verdictFollow-upQ2 FY2707 Nov 20266 minPharma & Healthcare

Strong YoY growth masks QoQ PAT collapse; Africa expansion bullish but unquantified

biologicals pipeline · Africa expansion · regulatory tightening

TranscriptDeep diveQ2 FY2707 Nov 20266 minPharma & Healthcare

Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%

animal health · vaccines · poultry healthcare

ResultsQ2 FY2705 Nov 20263 minPharma & Healthcare
Latest
Board Meeting5 Nov, 11:13 am

Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%

Hester Biosciences' consolidated (primary) revenue came in at ₹97.91 Cr, up 38% YoY and 27% QoQ, with PAT of ₹20.63 Cr, up 44% YoY as reported (~41% on an adjusted basis stripping a minor ₹0.42 Cr exceptional gain this quarter — the year-ago quarter had no exceptional items, so the YoY comparison is largely clean). Standalone, the core India entity, posted revenue of ₹82.93 Cr (+28% YoY) and PAT of ₹16.66 Cr (+131% YoY). This is a micro-cap with no analyst consensus coverage located for this print, so street expectations are unknown rather than beaten or missed. The growth was margin-led as much as volume-led: standalone gross margin rose to 78% from 68% a year ago and EBITDA margin to 35% from 21%, which management attributes to a favourable product mix and cost discipline; consolidated EBITDA margin expanded to 37% from 33%. Poultry Healthcare (standalone) grew revenue 27% YoY on institutional penetration and customer engagement, while Animal Healthcare grew 34% YoY in the quarter on tender execution — though H1 Animal Healthcare revenue is still down 14% YoY on a weak Q1 tender cycle, a seasonality/timing effect rather than demand loss. Management's own framing credits consolidated growth primarily to "the strong performance of the India business," with international operations "broadly stable." Management gave no formal FY27 revenue or margin guidance at the last concall and none accompanies this result either; that stance is unchanged. The headline QoQ swing — consolidated PAT down 79% from ₹96.73 Cr in Q1 FY27 — is not a deterioration: Q1's figure was inflated by an ₹85.77 Cr non-recurring gain after Hester Africa's loan with the Gates Foundation was amended (principal cut from USD 12 Mn to USD 5 Mn, accrued interest waived, remaining balance made interest-free), booked as an Ind AS 109 extinguishment gain. Stripped of that, Q2's underlying consolidated performance is a sequential improvement, not a decline. Alongside results, the board approved a fresh unsecured USD 1 Mn loan to Hester Africa (9% interest, 3-year tenure) and the company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd, concluding the partial exit begun with last year's 43.81% stake sale. Going into Q3, the "Way Forward" section repeats existing priorities — poultry growth, Animal Healthcare portfolio refinement, vaccine/regulatory pipeline progress (including PPR, Goat Pox, and export registrations), manufacturing efficiency, and export market development — without new numeric targets, consistent with management's prior refusal to commit to specific FY27 figures.

5 Nov 2026, 11:13 am

Corporate Events

Board MeetingHESTERBIO
2026
5Nov

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingHESTERBIO
2026
6Oct

Board Meeting

The Board of Directors of the Company considered and approve…

BSE Filing ↗
Board MeetingHESTERBIO
2026
30Jul

Board Meeting

The Board of Directors have approved the unaudited Standalon…

BSE Filing ↗
Board MeetingHESTERBIO
2026
21Jul

Board Meeting

The 39th Annual General Meeting of Hester Biosciences Limite…

BSE Filing ↗
DividendHESTERBIO
2026
14Jul

₹11 / share

BSE Filing ↗
Board MeetingHESTERBIO
2024
28Oct

Board Meeting

Consider and approve the unaudited standalone and consolidat…

BSE Filing ↗
Board MeetingHESTERBIO
2024
2Aug

Board Meeting

Consider and approve the unaudited standalone financial resu…

BSE Filing ↗
Board MeetingHESTERBIO
2024
10May

Board Meeting

consider and approve audited standalone and consolidated fin…

BSE Filing ↗
Board MeetingHESTERBIO
2024
2Feb

Board Meeting

Consideration and approval of standalone and consolidated un…

BSE Filing ↗
Board MeetingHESTERBIO
2023
7Nov

Board Meeting

Consider and approve the standalone and consolidated unaudit…

BSE Filing ↗
DividendHESTERBIO
2023
13Sep

₹0.08 / share

BSE Filing ↗
Board MeetingHESTERBIO
2023
8Aug

Board Meeting

consider and approve the standalone and consolidated unaudit…

BSE Filing ↗